ReviewAJOG global reports2026
Prevalence and spectrum of variants in homologous recombination repair genes in ovarian cancer in Latin America: a systematic review and meta-analysis.
Review in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is a major cause of gynecologic cancer mortality worldwide, with disproportionately poor outcomes in Latin America (LATAM). Variants in homologous recombination repair genes, especially
objectiveTo synthesize the prevalence and spectrum of pathogenic and likely pathogenic variants in homologous recombination repair pathway genes among LATAM ovarian cancer patients and highlight clinical and research implications. STUDY
designThe review protocol was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and was registered in the international prospective register of systematic reviews (PROSPERO; registration number CRD420251019706). We systematically searched MEDLINE, EMBASE, Scopus, Web of Science, LILACS, Cochrane, and Epistemonikos through April 2025. Eligible studies included LATAM ovarian cancer patients tested with multigene panels covering homologous recombination repair genes beyond
resultsEight studies published between 2017 and 2023, including 442 patients with ovarian cancer from Brazil, Argentina, Mexico, Chile, and Colombia, were included in the systematic review. Following variant curation and reclassification, 7 studies comprising 433 patients and 96 pathogenic/likely pathogenic homologous recombination repair variant carriers were retained for prevalence analysis, yielding a crude prevalence of 22.2%. Pathogenic variants predominated (91.7%), with
conclusionThis first systematic synthesis of homologous recombination repair variants in LATAM ovarian cancer reveals a predominance of Implications for Practice: This systematic review highlights both opportunities and barriers for implementing homologous recombination repair testing in ovarian cancer across Latin America. While
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.